RVMD Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 12.65%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Electromed, Inc.'s return on equity of 18.89%.

Revolution Medicines, Inc. has a consensus price target of $83.26, signalling upside risk potential of 3.11%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 26.32%. Given that Electromed, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Electromed, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 3.80x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Disc Medicine, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of --. Revolution Medicines, Inc.'s return on equity of -51.27% beat Disc Medicine, Inc.'s return on equity of -32.82%.

Revolution Medicines, Inc. has a consensus price target of $83.26, signalling upside risk potential of 3.11%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $121.67 which suggests that it could grow by 51.46%. Given that Disc Medicine, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Disc Medicine, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.406%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Disc Medicine, Inc. quarterly revenues of --. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solid Biosciences, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of --. Revolution Medicines, Inc.'s return on equity of -51.27% beat Solid Biosciences, Inc.'s return on equity of -77.74%.

Revolution Medicines, Inc. has a consensus price target of $83.26, signalling upside risk potential of 3.11%. On the other hand Solid Biosciences, Inc. has an analysts' consensus of $15.23 which suggests that it could grow by 160.8%. Given that Solid Biosciences, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Solid Biosciences, Inc. has a beta of 2.975, suggesting its more volatile than the S&P 500 by 197.54%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solid Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Solid Biosciences, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Solid Biosciences, Inc. quarterly revenues of --. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Solid Biosciences, Inc.'s net income of -$45.8M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Solid Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 20.36x for Solid Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 3.93%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Revolution Medicines, Inc. has a consensus price target of $83.26, signalling upside risk potential of 3.11%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.